Changes after 12 years of follow-up severe asthma patients cohort: higher obstruction and comorbidities, but significant better quality of life

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorJR, N. G. Santos
dc.contributor.authorLIMA, R. M.
dc.contributor.authorATHANAZIO, R. A.
dc.contributor.authorPINTO, R. M. Carvalho
dc.contributor.authorRABE, K.
dc.contributor.authorCUKIER, A.
dc.contributor.authorSTELMACH, R.
dc.date.accessioned2024-02-15T15:03:09Z
dc.date.available2024-02-15T15:03:09Z
dc.date.issued2023
dc.description.abstractBackground The Brazilian Cohort of Asthma Sao Paulo (BRASASP) had a well-characterized severe asthmatic in Brazil, with 12 years of follow-up under standard treatment. Methods Sequential assessment of patients with uncontrolled asthma from BRASASP cohort was carried out with 12 years of follow-up, performing exams and comparing with previous measurements. Results 50 from the 60 initial patients were reevaluated. Twelve years later, FEV1 and the FEV1/FVC ratio have significantly decreased, with a rate of loss of lung function of 11.8 and 14%, respectively, and worsening in small airway parameters such as RV/TLC. BMI, The Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ) scores haven't changed. However, exacerbations decreased by 56%. Mean daily inhaled corticosteroid use was similar over time, but daily oral corticosteroid use decreased, in addition to a significant reduction in induced sputum eosinophilic and neutrophilic profile and serum IgE. Rhinitis, sinusitis, and GERD were the main comorbidities. In quality of life according to respiratory questionnaire SGRQ, total score showed a huge improvement (62% of patients). Conclusions There was significant decrease in FEV1 and FEV1/FVC. Data of pulmonary functional small airway characteristics show globally affected airways. Although higher doses of medications, patients were still uncontrolled, but with reduction of exacerbations, daily use of oral corticosteroid, less eosinophils and neutrophils in induced sputum and lower levels of IgE. Improvement in quality of life in 62% of patients.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.description.sponsorshipAstraZeneca Brazil [ESR-17-13208]
dc.identifier.citationJOURNAL OF ASTHMA, v.60, n.2, p.298-303, 2023
dc.identifier.doi10.1080/02770903.2022.2045311
dc.identifier.eissn1532-4303
dc.identifier.issn0277-0903
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/58311
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTDeng
dc.relation.ispartofJournal of Asthma
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright TAYLOR & FRANCIS LTDeng
dc.subjectAsthmaeng
dc.subjectasthma controleng
dc.subjectairway inflammationeng
dc.subjectairway obstructioneng
dc.subjectquality of lifeeng
dc.subject.otherto-treat asthmaeng
dc.subject.wosAllergyeng
dc.subject.wosRespiratory Systemeng
dc.titleChanges after 12 years of follow-up severe asthma patients cohort: higher obstruction and comorbidities, but significant better quality of lifeeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryAlemanha
hcfmusp.affiliation.countryisode
hcfmusp.author.externalRABE, K.:German Ctr Lung Res, Airway Res Ctr North, LungenClin Grosshansdorf, Grosshansdorf, Germany
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcNILTON GONCALVES DOS SANTOS JUNIOR
hcfmusp.contributor.author-fmusphcRENATO MIRANDA LIMA
hcfmusp.contributor.author-fmusphcRODRIGO ABENSUR ATHANAZIO
hcfmusp.contributor.author-fmusphcREGINA MARIA DE CARVALHO PINTO
hcfmusp.contributor.author-fmusphcALBERTO CUKIER
hcfmusp.contributor.author-fmusphcRAFAEL STELMACH
hcfmusp.description.beginpage298
hcfmusp.description.endpage303
hcfmusp.description.issue2
hcfmusp.description.volume60
hcfmusp.origemWOS
hcfmusp.origem.pubmed35274580
hcfmusp.origem.scopus2-s2.0-85128066238
hcfmusp.origem.wosWOS:000776219400001
hcfmusp.publisher.cityABINGDONeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.reference[Anonymous], 2020, GINA GLOBAL INITIATIeng
hcfmusp.relation.referenceAthanazio R, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0314-1eng
hcfmusp.relation.referenceBel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643eng
hcfmusp.relation.referenceChipps BE, 2018, J ALLERGY CLIN IMMUN, V141, P1590, DOI 10.1016/j.jaci.2017.07.014eng
hcfmusp.relation.referencede Carvalho-Pinto RM, 2012, RESP MED, V106, P47, DOI 10.1016/j.rmed.2011.08.013eng
hcfmusp.relation.referenceIsrael E, 2017, NEW ENGL J MED, V377, P965, DOI 10.1056/NEJMra1608969eng
hcfmusp.relation.referencePostma DS, 2019, LANCET RESP MED, V7, P402, DOI 10.1016/S2213-2600(19)30049-9eng
hcfmusp.relation.referenceRay A, 2016, J CLIN INVEST, V126, P2394, DOI 10.1172/JCI84144eng
hcfmusp.scopus.lastupdate2024-05-19
relation.isAuthorOfPublication4143c2ac-2111-48e9-9464-c95a6bc0cf9b
relation.isAuthorOfPublication723b93b3-2712-4924-8b71-fe1a9dba37f1
relation.isAuthorOfPublicationdda28bde-464b-4f59-94b0-5a51fc353f5e
relation.isAuthorOfPublicationb881b3ab-c713-4db6-a7cd-a4a429f144fb
relation.isAuthorOfPublicationb85faf4f-dfcf-46fb-bac2-dca71f90f4d1
relation.isAuthorOfPublication3d54f378-0390-4e1c-9631-3f523a529ebb
relation.isAuthorOfPublication.latestForDiscovery4143c2ac-2111-48e9-9464-c95a6bc0cf9b
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_JR_Changes_after_12_years_of_followup_severe_asthma_2023.PDF
Tamanho:
981.55 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - LIM/09
Artigos e Materiais de Revistas Científicas - ODS/03